Evaluation of a new semi-automated Hydragel 11 von Willebrand Factor multimers assay kit for routine use

Evaluation of a new von Willebrand Factor multimers assay kit

  • Marika Pikta Department of Laboratory Medicine, North Estonia Medical Centre, Tallinn, Estonia; Department of Health Technologies, Tallinn University of Technology, Tallinn, Estonia https://orcid.org/0000-0002-5891-7589
  • Timea Szanto Coagulation Disorders Unit, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland
  • Margus Viigimaa Department of Health Technologies, Tallinn University of Technology, Tallinn, Estonia; Centre of Cardiology, North Estonia Medical Centre, Tallinn, Estonia
  • Sandra Lejniece Riga Stradins University, Riga, Latvia; Chemotherapy and Hematology Clinic, Riga East University Hospital, Riga, Latvia
  • Dārta Balode Riga Stradins University, Riga, Latvia; Chemotherapy and Hematology Clinic, Riga East University Hospital, Riga, Latvia
  • Kadri Saks Hematology Department, Tallinn Children`s Hospital, Tallinn, Estonia
  • Valdas Banys Vilnius University, Faculty of Medicine, Institute of Biomedical Sciences, Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Vilnius, Lithuania
DOI: https://doi.org/10.5937/jomb0-26008
Keywords: Electrophoresis, multimers, von Willebrand factor, von Willebrand disease

Abstract


Accurate diagnosis and classification of von Willebrand disease are essential for optimal management.  The von Willebrand factor multimers analysis is in the phenotypic classification, especially in discrepant cases, an integral part of the diagnostic process. The aim of this study was to evaluate the performance of a new Hydragel 11VWF multimer assay (H11VW). Results: Comparison study did not reveal any significant difference between H5VW and H11VW.  The assessment of within-subject results, using H5VW and H11VW, demonstrates the reproducibility of the method in both healthy and VWD patients’ samples collected over time, with identical multimeric pattern on densitometric curves.Conclusion: This assay demonstrated acceptable performance, produced within-day results and can be used in routine practice for the visual investigation of gel and quantitative estimation of VWF multimer fractions.

References

1. Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37(5): 440-55.
2. Szanto T, Lassila R, Funding E, et al. Von Willebrand disease—the Nordic perspective. Ann Blood 2018; 3: 2.
3. Nummi V, Lassila R, Joutsi-Korhonen L, et al. Comprehensive re-evaluation ofhistorical von Willebrand disease diagnosis in association with whole blood platelet aggregation and function. Int J Lab Hem 2018; 40: 304-311.
4. Roberts JC, Flood VH. Laboratory diagnosis of von Willebrand disease. Int J Lab Hematol 2015; 37(Suppl): 11‐17.
5. Torres R, Genzen JR, Levene MJ. Clinical Measurement of von Willebrand Factor by Fluorescence Correlation Spectroscopy. Clin Chem 2012; 58: 1010-1018
6. Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32: 485-491.
7. Ledford-Kraemer MR. Analysis of von Willebrand factor structure by multimer analysis. Am J Hematol 2010; 85: 510-514.
8. Oliver S, Lau KKE, Chapman K, Favaloro EJ. Laboratory testing for von Willebrand factor multimers. Methods Mol Biol 2017; 1646: 495–511
9. Crist RA, Heikal NM, Rodgers GM, Grenache DG, Smock KJ. Evaluation of a new commercial method for von Willebrand factor multimeric analysis. Int J Lab Hem 2018; 40: 586–591.
10. Favaloro EJ, Oliver S. Evaluation of a new commercial von Willebrand factor multimer assay. Haemophilia. 2017; 23: e373-e377.
11. Pikta M, Zemtsovskaja G, Bautista H, et al. Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers. J Clin Lab Anal 2018; 32: e22416.
12. Bowyer AE, Goodfellow KJ, Seidel H, et al. Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers. Res Pract Thromb Haemost 2018; 2: 790–799.
13. Pikta M, Zolotareva V, Tõnne J, Viigimaa M, Banys V. Implementation and Verification of New VWF: Ac Assay System with Components from Different Manufacturers. Laboratorine medicina 2016; 72: 185-188
14. Favaloro EJ. Rethinking internal quality control and external quality assessment for laboratory diagnostics of von Willebrand disease. Ann Blood 2019; 4: 4.
Published
2020/08/18
Issue
Vol. 40 No. 2 (2021): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2020 Marika Pikta

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.